拿着小瓶的男人
图片:在上面
2022年7月20

Groundbreaking OD电竞官方app research into developing new treatments for conditions such as cancer, inflammatory diseases and type 1 diabetes has received recognition and funding support from a national incubator for biomedical startup companies.

Working in partnership with University of OD电竞 researchers, OD电竞官方app commercialisation company 独特的 has secured $3 million in funding for the four startups under the first round of the Medical 研究 Future Fund (MRFF)’s national $40 million CUREator Scheme.

CUREator helps to rapidly progress preclinical research or early-stage clinical programmes to advanced proof of concept stage, 让他们“做好投资准备”.

独特的 CEO Dr Dean Moss said the funding for the four startups recognised OD电竞官方app’s leadership role in biomedical research, technology transfer and commercialisation.

“It’s an acknowledgement of how innovative research excellence from OD电竞官方app’s Institutes and 能力 is translated into real-world impact,莫斯博士说.

“The success of these four OD电竞官方app startups is testament to the incredible hard work and remarkable, high-quality knowledge that our researchers continue to produce.

“Each of these startups has the potential to develop new treatments for conditions with a large healthcare cost, which is an exciting prospect and I congratulate all involved.”

The four OD电竞官方app companies awarded funding are:

  • Cassowary Pharmaceuticals Pty Ltd – to develop treatment of neuropathic pain that is often poorly alleviated by current medications. 这建立在OD电竞官方app的研究基础上 医学院, Faculty of Health and Behavioural 科学s, 理学院澳大利亚n Institute for Bioengineering and Nanotechnology (AIBN).
  • Frontier Inflammasome Therapeutics Pty Ltd – to develop small molecule inhibitors involved in inflammatory diseases such as those resulting from viral respiratory infections. OD电竞官方app的开发 分子生物科学研究所 in collaboration with 独特的’s drug discovery incubator, the OD电竞 Emory Drug Discovery Initiative (QEDDI).
  • Carsinosa - to develop a first-of-its-kind oral small molecule drug to be used in the treatment of a range of difficult-to-treat cancers including metastatic prostate cancer, 乳腺癌, 卵巢癌和结肠癌. This is based on research initiated at OD电竞官方app’s Diamantina研究所 and progressed in collaboration with QEDDI.
  • Liperate Therapeutics Pty Ltd - awarded $1.5m for a clinical trial of an immune therapy at OD电竞官方app’s Diamantina Institute that aims to help preserve insulin production in recently diagnosed type 1 diabetes patients. This is to help them go for as long as possible without needing insulin. 

The CUREator Scheme is being run by Brandon BioCatalyst and aims to grow and support up to 40 promising preclinical and early-stage clinical companies across multiple funding rounds.

媒体:独特的, Esther Haskell, e.haskell@uniquest.com.au, +61 (0)409 767 199.